Serial No. 09/008,957 Amendment

believes there are no other rejections or objections to the claims.

<u>Remarks</u>

Applicants thank the Examiner for considering Applicants'
Amendment after Final Office Action. Included with that
Amendment was a Declaration by Dr. Robert Moriarty which provides
evidence that Applicants' claimed compound possess a key
unexpected property (reduced calcemic activity) amounting to a
marked superiority over the prior art compounds. However, the
Examiner indicated in her advisory action that "the declaration
does not show a statistically significant difference between the
prior art compound and the claimed compound." Applicants soon
will be submitting a statistically significant. Applicants
request that an Examination of the Continued Prosecution
Application not be conducted until Applicants provide the
Examiner with the statistical data the Examiner requested.

Serial No. 09/008,957 Amendment

The Examiner also stated that "the prior art teaches $1\alpha(OH)\,D_4$ and $1\alpha,25\,(OH)_2\,D_4$ which are closer to compounds of claims 2 and 3 than $1\alpha(OH)\,D_3$ and $1\alpha,25\,(OH)_2\,D_3$ shown in the declaration." In a telephone conversation with the Examiner, Applicants attorney pointed out that data for $1\alpha(OH)\,D_4$ does in fact appear in the declaration.

Respectfully submitted,

Harold J Fassnacht Reg. No. 35,507

BULLWINKEL PARTNERS, LTD. 19 S. LaSalle Street, Suite 1300 Chicago, Illinois 60603-1493 Telephone 312-201-0777

Dated: Feb 10 , 200



CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee, addressed to: Assistant Commissioner for Patents, Box CPA, Washington, DC 20231 on February 10, 2000. Express Mail No. EL214997374US.

Mary Winch Signature

Feb 10 2000